Skip to main
ZYME

Zymeworks Inc (ZYME) Stock Forecast & Price Target

Zymeworks Inc (ZYME) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zymeworks Inc. is experiencing a positive outlook driven by its innovative drug candidates, particularly zanidatamab, which demonstrates statistically significant improvements in progression-free survival and overall survival compared to control treatments, indicating strong clinical efficacy. The company's strategic transition towards a royalty-driven revenue model, highlighted by attractive compounding royalties from partnerships with JAZZ and JNJ, supports its financial strength, bolstered by a robust cash position and upcoming milestone payments. Additionally, the favorable safety profile and groundbreaking PD-L1-agnostic benefits present Zymeworks with substantial opportunities for NCCN Category 1 adoption, further enhancing its competitive positioning within the biopharmaceutical landscape.

Bears say

Zymeworks Inc faces a challenging outlook due to several key risks surrounding its clinical development and regulatory processes, specifically regarding its lead product, zanidatamab. The company's stock may experience significant downward pressure if clinical trials do not demonstrate sufficient efficacy or safety, potentially leading to development termination and impacting investor confidence. Additionally, the risks associated with competition, regulatory approval delays, and reliance on volatile capital markets for financing could further exacerbate long-term financial instability and dilution concerns, ultimately diminishing the perceived value of Zymeworks's pipeline.

Zymeworks Inc (ZYME) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zymeworks Inc (ZYME) Forecast

Analysts have given Zymeworks Inc (ZYME) a Buy based on their latest research and market trends.

According to 10 analysts, Zymeworks Inc (ZYME) has a Buy consensus rating as of Apr 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zymeworks Inc (ZYME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.